ASCO
Refine search
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Biotechnology
In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001. We interviewed president and chief executive Stacy Lindborg on the long path to this moment—and what may lie ahead in the evolving ovarian cancer treatment landscape. 28 May 2025
Pharmaceutical
Germany’s Merck KGaA today announced the presentation of detailed positive results from Part 1 of the global Phase III MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics, in the treatment of patients with tenosynovial giant cell tumor (TGCT). 28 May 2025
Biotechnology
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. 27 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Biotechnology
Swiss pharma major Roche has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Pharmaceutical
UK pharma major AstraZeneca is set to present data from more than 80 studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Spanning across 20 approved and investigational medicines, the presentations include two plenary sessions and a special late-breaking abstract. 22 May 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of Cancer Oncology (ASCO) meeting across its expansive cancer portfolio. 21 May 2025
Live
Welcome to The Pharma Letter’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. This feed will deliver concise updates as they happen—check back here regularly for headline trial results, regulatory milestones, practice updates and more. 21 May 2025
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Pharmaceutical
US analytics specialist Phesi has called for a major rethink in how oncology trials are planned and run, saying clinical development has failed to keep pace with scientific progress. 15 May 2025
Pharmaceutical
US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 14 May 2025
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze